196 related articles for article (PubMed ID: 36206367)
21. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
22. An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy.
Li W; Zhu X; Zhou X; Wang X; Zhai W; Li B; Du J; Li G; Sui X; Wu Y; Zhai M; Qi Y; Chen G; Gao Y
J Control Release; 2021 Jun; 334():376-388. PubMed ID: 33940058
[TBL] [Abstract][Full Text] [Related]
23. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
Zhang L; Zhao X; Niu Y; Ma X; Yuan W; Ma J
J Extracell Vesicles; 2023 Nov; 12(11):e12379. PubMed ID: 37974395
[TBL] [Abstract][Full Text] [Related]
24. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
25. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
26. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
Yang J; Chen J; Liang H; Yu Y
Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
[TBL] [Abstract][Full Text] [Related]
27. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
29. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
[TBL] [Abstract][Full Text] [Related]
30. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
32. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
33. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
35. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint.
Gu T; Tian X; Wang Y; Yang W; Li W; Song M; Zhao R; Wang M; Gao Q; Li T; Zhang C; Kundu JK; Liu K; Dong Z; Lee MH
Front Immunol; 2023; 14():1145028. PubMed ID: 37205112
[TBL] [Abstract][Full Text] [Related]
36. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
38. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
39. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
40. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
